Any current/future new fundraising through debt or equity?

There is no mention of any current or planned new fundraising through debt or equity in the Q3 FY’25 earnings call transcript. The company states it is "cash-rich" with a cash and investment balance of ₹190 crores as of Q3 FY’25. Investments have been internally funded, for example, CAPEX spent on a Tier 3 data center in Pune. The focus appears to be on organic growth, strategic hiring, product launches, and expanding order book without external fundraising. No public disclosures or comments about raising new capital through debt or equity were made during the call.

Any current/future capex/capital investment/strategic investment?

The company has made capital expenditure on a Tier 3 data center at their Pune office, involving a significant CAPEX spend. Despite this investment, the cash balance remains steady at around Rs. 190 crores. There are no specific future capex plans detailed in the call, but the company mentions continuous investments in new product launches like AntiFraud and Horizon 3 categories. Strategic investments include partnerships and MOUs with institutions such as the Banking Institute of Rural Development Lucknow, NFSU, and IIM Nagpur to foster collaborative research in cybersecurity. The focus on R&

Future growth expectations in sales/revenue/volumes?

Quick Heal has a healthy pipeline and growing order book, indicating confidence in FY’26 outlook. Enterprise order book has reached material size (₹7.2 crores) with deferred revenue building up (₹10 crores), providing revenue visibility and predictability. New product launches like AntiFraud.AI, Seqrite Malware Analysis, and Seqrite Threat Intelligence target emerging enterprise cybersecurity needs, expected to drive future sales. DPDP and cybersecurity regulatory compliance expected to boost sales across data privacy and cybersecurity products; average deal size for mid-market ₹75 lakhs

Future growth expectations in earnings/operating earnings/profits/EPS?

Q3 FY’25 showed a muted performance with a 4% QoQ revenue decline and 14% YoY decline due to headwinds in consumer and government verticals. Company confident in FY’26 outlook, backed by a healthy enterprise pipeline and growing order book and deferred revenue, providing better predictability. Investments in Horizon 3 product launches (e.g., AntiFraud.AI) may pressure short-term profitability but aim to drive long-term growth. EBITDA was negative INR 3.8 crore in Q3 FY’25; however, 9-month EBITDA stood at INR 1.9 crore. PAT for Q3 FY’25 was INR 0.1 crore, indicating near breakeven. Expect grow

Current/ Expected Orderbook/ Pending Orders?

Quick Heal's enterprise order book as of Q3 FY'25 stands at ₹7.2 crores, a significant increase from ₹35 lakhs at the end of Q2. Deferred revenue has grown by around ₹8 crores over the past 9 months, totaling ₹10 crores at the end of Q3 FY'25. The order book primarily consists of confirmed purchase orders/contracts, mainly from enterprise customers, domestic and international. These orders typically span over contract tenures of 1 to 3 years. The order book and deferred revenue are additional to the current quarterly enterprise revenue run rate of around ₹30 crores. This is the first time Quic

IN US

Sale is live|00:00:00left today

Quick Heal Technologies LtdQ4 FY26IT - Software

Quick Heal Technologies Ltd Q4 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹177P/E: 196.4Market Cap: ₹1.1K CrSector: IT - Software

Management growth scorecard

Revenue

Category 3

Margin

Category 4

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Quick Heal has a healthy pipeline and growing order book, indicating confidence in FY’26 outlook.
→Enterprise order book has reached material size (₹7.2 crores) with deferred revenue building up (₹10 crores), providing revenue visibility and predictability.
→New product launches like AntiFraud.AI, Seqrite Malware Analysis, and Seqrite Threat Intelligence target emerging enterprise cybersecurity needs, expected to drive future sales.
→DPDP and cybersecurity regulatory compliance expected to boost sales across data privacy and cybersecurity products; average deal size for mid-market ₹75 lakhs to ₹3 crores.
→Consumer segment industry facing de-growth, but Quick Heal plans a flattish revenue trend and increased marketing efforts, e.g. for AntiFraud product.
→Strategic hiring and academy business aim to build capacity and drive market expansion.
→Overall, focus on innovation, strategic partnerships, and new product pipeline expected to underpin growth and value creation.

Margin guidance

Category 4

→Q3 FY’25 showed a muted performance with a 4% QoQ revenue decline and 14% YoY decline due to headwinds in consumer and government verticals.
→Company confident in FY’26 outlook, backed by a healthy enterprise pipeline and growing order book and deferred revenue, providing better predictability.
→Investments in Horizon 3 product launches (e.g., AntiFraud.AI) may pressure short-term profitability but aim to drive long-term growth.
→EBITDA was negative INR 3.8 crore in Q3 FY’25; however, 9-month EBITDA stood at INR 1.9 crore.
→PAT for Q3 FY’25 was INR 0.1 crore, indicating near breakeven.
→Expect growth from expanding enterprise business, strategic partnerships, and new product launches like DPDP compliance, threat intelligence, and malware analysis.
→Order book and deferred revenue are building, signaling more stable and predictable future revenues.
→Emphasis on innovation and market expansion supports a transformational pivot expected to yield earnings growth over time.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no mention of any current or planned new fundraising through debt or equity in the Q3 FY’25 earnings call transcript.
→The company states it is "cash-rich" with a cash and investment balance of ₹190 crores as of Q3 FY’25.
→Investments have been internally funded, for example, CAPEX spent on a Tier 3 data center in Pune.
→The focus appears to be on organic growth, strategic hiring, product launches, and expanding order book without external fundraising.
→No public disclosures or comments about raising new capital through debt or equity were made during the call.

Order book

Yes

→Quick Heal's enterprise order book as of Q3 FY'25 stands at ₹7.2 crores, a significant increase from ₹35 lakhs at the end of Q2.
→Deferred revenue has grown by around ₹8 crores over the past 9 months, totaling ₹10 crores at the end of Q3 FY'25.
→The order book primarily consists of confirmed purchase orders/contracts, mainly from enterprise customers, domestic and international.
→These orders typically span over contract tenures of 1 to 3 years.
→The order book and deferred revenue are additional to the current quarterly enterprise revenue run rate of around ₹30 crores.
→This is the first time Quick Heal is reporting a material enterprise order book, reflecting higher business predictability.
→The order book and deferred revenue provide comfort on future revenue visibility beyond the existing run rate.

Capex plans

Yes

→The company has made capital expenditure on a Tier 3 data center at their Pune office, involving a significant CAPEX spend.
→Despite this investment, the cash balance remains steady at around Rs. 190 crores.
→There are no specific future capex plans detailed in the call, but the company mentions continuous investments in new product launches like AntiFraud and Horizon 3 categories.
→Strategic investments include partnerships and MOUs with institutions such as the Banking Institute of Rural Development Lucknow, NFSU, and IIM Nagpur to foster collaborative research in cybersecurity.
→The focus on R&D and innovation indicates ongoing strategic investments in new product development and market expansion.

How does Quick Heal Technologies Ltd rank vs peers in IT - Software?

Pro feature

1Quick Heal Technologies Ltd

Rev 3Mar 4

See full IT - Software sector rankings

Want more stocks like Quick Heal Technologies Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio